To better understand MAPS members’ perspectives on AI, Open Health recently convened a panel discussion on the future of data, AI, and analytics in Medical Affairs.
In today’s rapidly evolving pharmaceutical environment, Medical Affairs teams are under increasing pressure to understand how to go beyond “activity engagement” metrics and identify areas of opportunity to advance evidenced-based medicine and treatment with current available data.
This webinar will provide a historical perspective on value, as well as insights to help Medical Affairs professionals measure and demonstrate the impact of their activities in a complex environment.
As Medical Affairs teams strive to identify areas of opportunity and demonstrate their value, understanding the importance of data-driven strategies is essential. In this webinar, we will discuss the historical perspective on value in Medical Affairs, as well as strategies to measure and demonstrate impact in an evolving pharmaceutical environment. Join us to learn more about how data-driven strategies can help you gain a better understanding of your Medical Affairs activities and provide insights into areas of opportunity.
In this white paper, Triducive asks: Where is MA now? How are we progressing? Which areas may need the greatest additional effort/support?
Medical Affairs plays a critical strategic role in product launches, through scientific knowledge, clinical expertise and cross-functional collaboration. Comprehensive research of international product launches, with an objective set of criteria, has shown that less than 10% of recent launches were excellent. This research has also revealed that two key dimensions, unmet need and product differentiation, have the highest influence on launch success, and enabled the definition of four clear launch archetypes. The launch archetypes help to identify critical success factors (CSFs) to develop the most effective launch strategy, and facilitate launch planning. The CSFs also highlight the key areas where Medical Affairs can make the highest strategic impact to support product success and improve patient outcomes.
Through review of launch archetypes, product launch case studies and MAPS launch excellence guidelines, this webinar will examine, based on the prevailing pre-launch situation, the strategic focus areas for Medical Affairs teams to consider during launch preparation and discuss approaches to achieve excellence across key activities.
The session will focus on results from first hand experiences in Chat GPT and other Large Language Models (LLMs), themes will include:
Medical congresses are crucial for keeping up with the latest life science industry standards and best practices – but planning is time-consuming and manual. What’s the alternative for better medical congress planning? Get the complete guide to congress planning.
This case study is useful for anyone working to anticipate market access issues and develop plans for launching new drugs in key markets.
With the vast amount of data available today, Medical Affairs organizations are tasked with continuously enhancing their ability to gather, analyze and derive insights from various data sources. Information is compounding at an increasingly faster pace and, if harnessed effectively, can allow Medical Affairs executives to make insight-driven decisions that drive company-wide strategy. This presentation will focus on:
In this episode, Ariel Katz, co-Founder and CEO of H1, provides a more linear and streamlined vision for how Medical Affairs can impact patient outcomes — and how to measure the results of our actions.
This session will 1) Discuss why patient inclusion is important for Medical Affairs Professionals 2) Look at processes and potential barriers to inclusion of the patient perspective in Medical Affairs deliverables and development of clinical trial protocols; 3) Provide you with the resources to successfully establish a compliant process for patient engagement; and 4) will ultimately provide insights on how to work with patients in a compliant manner.